IM Cannabis

The company's journey began with a focus on the Israeli medical cannabis market, where it built a significant presence. A key milestone in its history was the reverse takeover of a Canadian-listed company, which facilitated its public listing on the Canadian Securities Exchange (CSE) under the ticker 'IMCC' and later on the NASDAQ. This strategic move provided access to capital markets to fund its international expansion. The leadership team, including CEO Oren Shuster, has guided the company through complex international regulations and market entries.

IM Cannabis's revenue is generated through the sale of branded medical and recreational cannabis products. In Israel, it operates through a network of pharmacies and supplies its brand, IMC, with products sourced from its own cultivation facility and other suppliers. In Germany, the company functions as a distributor, importing cannabis to supply pharmacies within the country's growing medical market. The Canadian operations have included the Trichome Financial brand, which focused on the adult-use market with brands like WAGNERS and Highland Grow. This multi-jurisdictional approach allows the company to tap into different stages of market maturity, from the established Canadian market to the evolving European landscape.

The product portfolio consists of dried cannabis flower, pre-rolls, and oils, tailored to the preferences of patients and consumers in each region. The company emphasizes quality control and consistent supply to build brand loyalty in competitive markets. By controlling various parts of the supply chain, from cultivation and sourcing to final sale, IM Cannabis aims to manage costs and ensure product quality, positioning itself as a significant player in the global cannabis industry.